Annexon (ANNX) news
Recent news
Annexon shares fall 5.3% after wider-than-expected Q2 net loss
AInvest Wire · Aug 12, 2026Annexon shares fall 6.4% premarket after wider-than-expected Q2 net loss
Annexon Inc. (Nasdaq: ANNX) shares fell 6.4% in premarket trading on August 12, 2026, following the release of its second-quarter 2026 financial results, which showed a wider-than-expected net loss. The company reported GAAP net loss per share of $0.34 for the quarter, exceeding the consensus…
AInvest Wire · Aug 12, 2026Annexon reports second quarter 2026 financial results, business updates and key anticipated milestones
Annexon, Inc. (Nasdaq: ANNX) reported its second quarter 2026 financial results and provided updates on key business developments and upcoming milestones. As of March 31, 2026, the company held $225.0 million in cash, cash equivalents, and short-term investments, with a projected operating runway…
AInvest Wire · Aug 12, 2026Annexon Biosciences Q2 basic EPS USD -0.28
Annexon Biosciences (Nasdaq: ANNX) reported a basic earnings per share (EPS) of -$0.28 for the second quarter of 2026, reflecting continued net losses as the company advances its pipeline of therapies targeting classical complement-mediated neuroinflammatory diseases. This result aligns with the…
AInvest Wire · Aug 12, 2026Annexon Inc: Needham raises target price to $25 from $11
AInvest Wire · Jul 15, 2026Light Horse does not author, endorse or verify the headlines, and their appearance here is not an endorsement of any view they express.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.